Document mp5g9vDMeLnQdbQeDjQmrrxVd

PROGRAM Monday, September 7, 2009 7:00PM Reception and registration Tuesday, September 8, 2009 Platform Session 1: Co-chairs: Introduction to the symposium H. Greim, Technical University of Munich H. Bolt, University of Dortmund 8:00AM Greetings and welcome. H. Greim 8:20 A century of research on the hematotoxic effects of benzene; aims of the symposium. R. Snyder, Rutgers The State University of New Jersey and EOHSI. 8:40 Interpreting available data and identifying critical data gaps for benzene risk assessment. Contribution of the IPCS/ILSI framework for "Mode of Action/Human Relevance. B. Meek, University of Ottawa. Platform Session 2: Bone marrow and leukemia Co-chairs: R. Larson, University of Chicago M. Trush, Johns Hopkins University School of Public Health. 9:00 Regulation of hematopoiesis by bone marrow stem cells. C. Peschel, Technical University of Munich 9:30 Regulation of hematopoiesis by the bone marrow environment. R. Oostendorp, Technical University of Munich 10:00 Break Poster Session 1 Co-chairs: D. Kaden, Health Effects Institute S. Gross, University of Colorado Platform Session 1 (continued) 10:30 WHO classification of hematopoietic neoplasms. J. Vardiman, University of Chicago. 11 :00 Integrating WHO 2001-2008 criteria for the diagnosis of hematopoietic neoplasms: impact on benzene epidemiology. R. Irons, Fudan University of Shanghai. 11 :30 Incidence and susceptibility to t-AML. G. Leone, Catholic University of Rome. 12:00 Implications of latency period between benzene exposure and risk of leukemia. G. Triebig, University of Heidelberg 12:30 Chromosome pathways, genetic changes, cooperating mutations, and candidate genes in primary and therapy related MDS and AML. M. Le Beau, University of Chicago. 1:00 Lunch Poster session 1 (continued) [APG] CGU BEN0001200 Platform Session 2 (continued) 2:00 MicroRNA, epigenetics, and copy number changes: New levels of gene regulation in AML. R. Larson, University of Chicago. 2:30 Epigenetic changes in therapy-related MDS/AML. M.T. Voso, Catholic University of Rome Platform Session 3: Co-chairs: Recent studies and re-evaluation of data on the epidemiology of benzene-induced diseases. E. Taioli, SUNY, Downstate Medical Center P. Boogaard, Shell Health 3:00 A pooled analysis of case controlled studies on benzene exposure in petroleum workers. D. Glass, Monash University Australia. 3:30 Break Poster Session 1 (continued) 4:00 Benzene as a cause of myeloproliferative disorders. B.D. Goldstein, University of Pittsburgh. 4:30 Shanghai Health Study: Case control studies. 4:30-4:50 Acute myeloid leukemia. 0. Wong, Applied Health Sciences. 4:50-5:10 Lymphoid neoplasms. Hua Fu, Fudan University 5:10- 6:00 Poster session 1 (continued) Wednesday, September 9, 2009 Platform Session 3 (continued) 8:00a.m. Effects of benzene exposure and SNPs in peripheral blood of workers in Shanghai. R. Schnatter, Exxon Biomedical Sciences. 8:30 Benzene and childhood leukemia. D. Pyatt, Summit Toxicology. Platform Session 4: Co-chairs: Mechanistic studies: Reactive metabolites and reactive oxygen species. F. Oesch, University Mainz, D. Schrenk, University Kaiserslautern 9:00 Fate of benzene oxide. T. Monks, University of Arizona 9:30 Elevated expression of CYP4F3 in peripheral white blood cells of benzenepoisoned patients and HL-60 cells exposed to benzene metabolites. Yongyi Bi, Wuhan University, China 10:00 Break 10:30 Modeling the formation and reactions of benzene metabolites. B.T. Golding, University of Newcastle Upon Tyne. 11 :00 Benzene metabolites block gap junction intercellular communication. E, Rivedal, Norwegian Radium Hospital, Oslo 11 :30 Biological activity of hydroquinone thiol conjugates. S. Lau, University of Arizona. [APG] CGU BEN0001201 12:00 Modulation of ROS in myeloid cells, M. Trush, Johns Hopkins University 12:30 Systems biology of benzene exposure. L. Zhang, University of California, Berkeley. 1:00 Lunch and excursion Thursday, September 10, 2009 Platform Session 5: Co-chairs: Mechanistic studies: Transgenics and signal transduction. H. Autrup, University of Aarhus A. Boobis, Imperial College, London 8:00a.m. Genetic susceptibility to benzene toxicity in multiple mouse models of human disease. J. French, National Institute of Environmental Health Sciences, 8:30 Hematopoietic neoplastic diseases in C3H/He and C57BL/6 mice after benzene exposure. Differences observed using microarrays. T. Inoue, National Institute of Safety and Health, Tokyo. 9:00 The Ah receptor has an important roe to play in the regulation of hematopoiesis. T. Gasiewicz, University of Rochester. 9:30 Benzene-induced toxicity is based on the AhR-mediated hematopoietic stem cells. Y. Hirabayashi, National Institute of Safety and Health, Tokyo. 10:00 Break Poster Session 2 Co-chairs: D. Pyatt, Summit Toxicology C. Weisel, EOHSI and UMDNJ Platform Session 5 (continued) 10:30 Benzene-initiated oxidative stress: effects on embryonic signaling pathways. L. Winn, Queens University, Canada 11 :00 Metabolic factors in susceptibility to benzene toxicity. D. Ross, University of Colorado 11 :30 Volunteer presentation to be selected Platform Session 6: Co-chairs: Mechanistic studies: DNA repair and chromosome damage S. Kyrtopoulos, National Helenic Research Foundation, Athens M. Ruchirawat, Chulaborn Research Institute, Bangkok. 12:00 The role of DNA repair in chemical carcinogenesis with special emphasis on benzene. A. Hartwig, Berlin Institute of Technology. 12:30 DNA repair and t-AML. P. Karran, Cancer Research, London 1:00 Lunch Poster Session 2 (continued) 2:00 Topoisomerase II, chromosome damage and leukemia. D. Eastmond, University of California, Riverside. 2:30 Effects of benzene metabolites on chromosomes. M. Gartenberg, UMDNJ [APG] CGU BEN0001202 Platform Session 7: Co-chairs: Exposure science and biomarkers P. Lioy, UMDNJ P. Farmer, University of Leicester. 3:00 Implications of exposure science and application to risk assessment. P. Lioy, EOHSI and UMDNJ. 3:30 Measuring benzene exposure. C. Weisel, EOHSI and UMDNJ. 4:00 Break Poster session 2 (continued) Platform Session 7 (continued) 4:30 Co-exposure studies of benzene with other hydrocarbons. M. Bird, ExxonMobil Biomedical Sciences. 5:00-6:00 Poster session 2 (continued) Friday, September 11, 2009 Platform Session 7. (continued) 8:00 Exposure assessment and biomarkers of benzene in China. S. Rappaport, University of California, Berkeley. 8:30 9:00 Biomarkers as probes: application on benzene toxicity., R. Albertini, University of Vermont Benzene exposure in Thailand. M. Ruchirawat, Chulaborn Research Institute Bangkok Platform Session 8. Co-chairs: Mode of action and risk assessment B. Sanawane, USEPA E. Dybing, Norwegian Institute of Public Health 9:30 Implication of recent data on benzene risk assessment. Weight of evidence for Mode of Action. Human relevance and dose-response; critical data gaps. J. Klaunig, University of Indiana. 10:00 The vanishing zero revisited: thresholds in the age of genomics. M.A. Gallo, EOHSI and UMDNJ. 10:30 Panel Discussion: Moderator: B. Meek, University of Ottawa Questions to the panel: a. What are the implications of recent data in relation to the weight of evidence for mode(s) of action of benzene-induced bone marrow damage and resulting risk? b. What are the critical data gaps in consideration of mode of action/human relevance? Panel: R. Albertini, H. Bolt, A. Boobis, D. Eastmond, B. Goldstein, L. Ziesse. 11:30 Summary of the panel discussion and comments on how the MOA approach can enhance future research on benzene. J. Klaunig. [APG] CGU BEN0001203 12:00 Close of symposium. H. Greim [APG] CGU BEN0001204